Shares of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) rose $13.75 during today’s regular trading session, a 33.95% increase from the previous closing price of $40.50. The company’s shares traded on stronger-than-usual volume today: $6.65M shares changed hands while the stock’s average volume is 408.77K shares per day. Aerie Pharmaceuticals, Inc. (AERI) has gained $11.95, or +28.25%, in the last 30 days. This year-to-date, the company’s shares have increased $16.40, or +43.33%. Over the last 12 months, AERI’s stock price has risen $37.59, or +225.63%. The company’s 52-week range is $16.28 to $51.85.
Aerie Pharmaceuticals, Inc. (AERI) Earnings Surprises
Aerie Pharmaceuticals, Inc. posted net revenue of 0M, beating Wall Street analysts who had forecast $0M. The company reported EPS of $-0.62, above the consensus estimate calling for EPS of $-0.67 – a negative surprise of -6.86%.
Before that, quarter ending December 2016, Aerie Pharmaceuticals, Inc. also surprised analysts by beating the consensus estimate. The Wall Street forecast had projected $-0.65 per share, and the company reported EPS of $-0.72 – also a -11.27% negative surprise. Revenue during the period amounted to $0M, while analysts were anticipating $0M.
In the quarter ending September 2016, Aerie Pharmaceuticals, Inc. delivered an even larger earnings beat. Analysts, on average, were expecting $-0.66 per share, and the company reported EPS of $-0.67 – amounting to a negative surprise of -1.30%. Revenue during that quarter was posted at $0M, whereas the consensus estimate was predicting $0M.
The company is scheduled to announce its next quarterly financial results on 02/08/2017 after the market close. The average EPS estimate of 2 Wall Street analysts is $-0.74 per share, compared to the company’s reported EPS of $-0.72 per share in the year-ago quarter. Analysts are forecasting Aerie Pharmaceuticals, Inc. to report revenue of about $0, versus the $0 posted last year.
Aerie Pharmaceuticals, Inc. (AERI) Consensus Estimates and Price Target
The company’s consensus rating is currently Strong Buy, with 7 analysts rating it a Strong Buy, and 1 analysts rating it with a Hold. The average 12-month price target, as forecast by analysts, is $62.11, 14.49% higher than the company’s closing price today.